Banyan Biomarkers Targets Protein Biomarkers to Detect Mild to Moderate Traumatic Brain Injury
4/23/2009 8:55:16 AM
GAINESVILLE, Fla.--(BUSINESS WIRE)--Banyan Biomarkers, Inc. today announced initiation of a multi-center, clinical feasibility study designed to demonstrate the effectiveness of the Company’s proprietary protein biomarkers, in detecting mild or moderate traumatic brain injury (MTBI). Banyan Biomarkers’ study will test a panel of biomarkers in blood from several hundred MTBI patients. The U.S. Department of Defense is providing funding to the Company to support the study. The results of the MTBI study will be submitted to the FDA in preparation for an Investigational Device Exemption pivotal trial. Ultimately, Banyan Biomarkers’ goal is to receive FDA approval for the Company’s biomarkers to be used as in vitro diagnostic blood tests for detecting mild to moderate brain injury.
comments powered by